A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells-Reference-Cited by-同舟云学术

A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells

Published:2020-05 Issue: Volume:125 Page:110033
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Wang Li,Zhan Yaqiong,Wu Zhe,Lin Mengjia,Jin Xuehang,Jiang Lushun,Qiu Yunqing

Funder

Science and Technology Department of Zhejiang Province

Zhejiang Province Science and Technology of Traditional Chinese Medicine Project

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference42 articles.

1. Therapeutic effects of amino acids in liver diseases: current studies and future perspectives;Lee;J. Cancer Prev.,2019

2. The diagnosis and treatment of hepatocellular carcinoma;Hartke;Semin. Diagn. Pathol.,2017

3. Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma;Sun;Cell. Physiol. Biochem.,2017

4. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma;Bruix;Gastroenterology,2016

5. New knowledge of the mechanisms of sorafenib resistance in liver cancer;Zhu;Acta Pharmacol. Sin.,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydrotanshinone Enhances The Anticancer Effects of Sorafenib on Hepatocellular Carcinoma by Inhibiting Akt Signaling Pathway Activation;PROG BIOCHEM BIOPHYS;2024

2. Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells;PLOS ONE;2024-03-25

3. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23

4. Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges;Pharmacological Research;2023-01

5. Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells;Scientific Reports;2022-10-25